184 related articles for article (PubMed ID: 26999580)
1. EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer.
Song L; Falzone N; Vallis KA
Int J Radiat Biol; 2016 Nov; 92(11):716-723. PubMed ID: 26999580
[TBL] [Abstract][Full Text] [Related]
2. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
Reilly RM; Kiarash R; Cameron RG; Porlier N; Sandhu J; Hill RP; Vallis K; Hendler A; Gariépy J
J Nucl Med; 2000 Mar; 41(3):429-38. PubMed ID: 10716315
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
Bailey KE; Costantini DL; Cai Z; Scollard DA; Chen Z; Reilly RM; Vallis KA
J Nucl Med; 2007 Sep; 48(9):1562-70. PubMed ID: 17704253
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy.
Fonge H; Lee H; Reilly RM; Allen C
Mol Pharm; 2010 Feb; 7(1):177-86. PubMed ID: 19924993
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy.
Thomas E; Menon JU; Owen J; Skaripa-Koukelli I; Wallington S; Gray M; Mannaris C; Kersemans V; Allen D; Kinchesh P; Smart S; Carlisle R; Vallis KA
Theranostics; 2019; 9(19):5595-5609. PubMed ID: 31534505
[TBL] [Abstract][Full Text] [Related]
6. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
[TBL] [Abstract][Full Text] [Related]
7. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
Cai Z; Chen Z; Bailey KE; Scollard DA; Reilly RM; Vallis KA
J Nucl Med; 2008 Aug; 49(8):1353-61. PubMed ID: 18632822
[TBL] [Abstract][Full Text] [Related]
8. Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX.
Cornelissen B; Waller A; Able S; Vallis KA
Mol Cancer Ther; 2013 Nov; 12(11):2472-82. PubMed ID: 23963362
[TBL] [Abstract][Full Text] [Related]
9. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
10. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157
[TBL] [Abstract][Full Text] [Related]
11.
Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM
Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375
[TBL] [Abstract][Full Text] [Related]
12. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
Cornelissen B; Darbar S; Hernandez R; Kersemans V; Tullis I; Barber PR; Smart S; Vojnovic B; Reilly R; Vallis KA
J Nucl Med; 2011 May; 52(5):776-83. PubMed ID: 21498540
[TBL] [Abstract][Full Text] [Related]
13. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of
Song L; Able S; Johnson E; Vallis KA
Nanotheranostics; 2017; 1(3):232-243. PubMed ID: 29071190
[TBL] [Abstract][Full Text] [Related]
15. Addressing brain tumors with targeted gold nanoparticles: a new gold standard for hydrophobic drug delivery?
Cheng Y; Meyers JD; Agnes RS; Doane TL; Kenney ME; Broome AM; Burda C; Basilion JP
Small; 2011 Aug; 7(16):2301-6. PubMed ID: 21630446
[TBL] [Abstract][Full Text] [Related]
16. Ligand Density and Nanoparticle Clustering Cooperate in the Multivalent Amplification of Epidermal Growth Factor Receptor Activation.
Zhang Q; Reinhard BM
ACS Nano; 2018 Oct; 12(10):10473-10485. PubMed ID: 30289688
[TBL] [Abstract][Full Text] [Related]
17. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
18. Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
Hu M; Scollard D; Chan C; Chen P; Vallis K; Reilly RM
Nucl Med Biol; 2007 Nov; 34(8):887-96. PubMed ID: 17998090
[TBL] [Abstract][Full Text] [Related]
19. Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation.
Chattopadhyay N; Cai Z; Kwon YL; Lechtman E; Pignol JP; Reilly RM
Breast Cancer Res Treat; 2013 Jan; 137(1):81-91. PubMed ID: 23160926
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors.
Kurihara A; Deguchi Y; Pardridge WM
Bioconjug Chem; 1999; 10(3):502-11. PubMed ID: 10346884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
